← Dashboard
Stock
JNJ
Johnson & JohnsonHealth CarePharmaceuticalsLatest close $2237 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
7
27 funds tracked
Ever held
12
Current + past
New this quarter
1
Exited this quarter
1
Marquee-fund ownership over time
Aug 14, 2013Feb 13, 2019Aug 9, 2024May 15, 2026
Now
7
This quarter's activity
New positions opened
Positions exited
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Bridgewater Associates re-entered | Q4 2013 | 51Q | $66 | $223 | +240% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $151 | $223 | +48% |
| Two Sigma Investments re-entered | Q3 2024(8Q snapshot) | 7Q | $151 | $223 | +48% |
| D.E. Shaw | Q3 2024(8Q snapshot) | 7Q | $151 | $223 | +48% |
| AQR Capital Management | Q3 2024(8Q snapshot) | 7Q | $151 | $223 | +48% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $151 | $223 | +48% |
| Soros Fund Management | Q2 2026(8Q snapshot) | 1Q | $227 | $223 | -1% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q3 2025 | Q2 2026 | → $227 | +32% |
| Renaissance Technologies 2× in & out | Q1 2025 | Q1 2026 | → $243 | +60% |
| Maverick Capital 3× in & out | Q2 2022 | Q1 2024 | → $145 | -8% |
| Berkshire Hathaway | Q3 2013 | Q4 2023 | → $136 | +118% |
| Duquesne Family Office | Q3 2013 | Q2 2014 | → $72 | +14% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at JOHNSON & JOHNSON. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
Filings · last 30d
12
Filings · last 90d
42
Total on file
492
Recent SEC buffer
Most recent
May 4, 2026
30d / 90d windows measured from May 4, 2026 — the most recent Form 4 on file — not from today.
- Form 40000200406-26-000115May 4, 2026
- Form 40000200406-26-000113Apr 27, 2026
- Form 40000200406-26-000111Apr 27, 2026
- Form 40000200406-26-000108Apr 27, 2026
- Form 40000200406-26-000106Apr 27, 2026
- Form 40000200406-26-000104Apr 27, 2026
- Form 40000200406-26-000102Apr 27, 2026
- Form 40000200406-26-000100Apr 27, 2026
- Form 40000200406-26-000098Apr 27, 2026
- Form 40000200406-26-000096Apr 27, 2026
- Form 40000200406-26-000094Apr 27, 2026
- Form 40000200406-26-000092Apr 27, 2026
- Form 40000200406-26-000070Mar 12, 2026
- Form 40000200406-26-000069Mar 12, 2026
- Form 40000200406-26-000067Mar 12, 2026
Showing 15 of 492 recent Form 4 filings. Browse all on EDGAR ↗
Fundamentals
XBRL · Johnson & JohnsonAnnual figures sourced directly from Johnson & Johnson's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Revenue
$94.19B
FY2025+6% YoY
Net income
$26.8B
FY2025+91% YoY
EPS (diluted)
$11.03
FY2025+91% YoY
Free cash flow(?)
$19.7B
FY2025-1% YoY
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for JOHNSON & JOHNSON — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventApr 28, 2026
- 10-QQuarterly reportApr 22, 2026
- 8-KMaterial eventApr 14, 2026
- DEF 14AProxy statementMar 11, 2026
- 10-KAnnual reportFeb 11, 2026
- 8-KMaterial eventJan 21, 2026
- 10-QQuarterly reportOct 22, 2025
- 8-KMaterial eventOct 14, 2025
- 8-KMaterial eventSep 9, 2025
- 10-QQuarterly reportJul 24, 2025
- 8-KMaterial eventJul 16, 2025
- 8-KMaterial eventJun 10, 2025
- 8-KMaterial eventApr 30, 2025
- 10-QQuarterly reportApr 23, 2025
- 8-KMaterial eventApr 15, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Soros Fund Management | Q2 2026 | open | $227 | $229 | +1% |
| Point72 Asset Management | Q3 2025 | Q2 2026 | $171 | $227 | +32% |
| Two Sigma Investments | Q1 2025 | open | $151 | $229 | +52% |
| Point72 Asset Management | Q1 2025 | Q2 2025 | $151 | $146 | -3% |
| Renaissance Technologies | Q1 2025 | Q1 2026 | $152 | $243 | +60% |
| Citadel Advisors | Q3 2024 | open | $151 | $229 | +52% |
| Two Sigma Investments | Q3 2024 | Q4 2024 | $151 | $145 | -3% |
| D.E. Shaw | Q3 2024 | open | $151 | $229 | +52% |
| AQR Capital Management | Q3 2024 | open | $151 | $229 | +52% |
| Millennium Management | Q3 2024 | open | $151 | $229 | +52% |
| Renaissance Technologies | Q3 2024 | Q4 2024 | $153 | $147 | -4% |
| Maverick Capital | Q2 2022 | Q1 2024 | $158 | $145 | -8% |
| Maverick Capital | Q3 2021 | Q1 2022 | $155 | $146 | -6% |
| Bridgewater Associates | Q4 2020 | open | $128 | $223 | +75% |
| Bridgewater Associates | Q2 2020 | Q3 2020 | $124 | $127 | +2% |
| Bridgewater Associates | Q3 2018 | Q1 2019 | $104 | $109 | +5% |
| Maverick Capital | Q3 2016 | Q3 2020 | $93 | $125 | +35% |
| Bridgewater Associates | Q3 2016 | Q1 2017 | $94 | $89 | -5% |
| Bridgewater Associates | Q4 2013 | Q2 2016 | $66 | $86 | +31% |
| Berkshire Hathaway | Q3 2013 | Q4 2023 | $63 | $136 | +118% |
| Duquesne Family Office | Q3 2013 | Q2 2014 | $64 | $72 | +14% |
Caveats
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.